Evidence for testicular impairment after long-term treatment with a luteinizing hormone-releasing hormone agonist in elderly men

A. U. Decensi, D. Guarneri, P. Marroni, L. Di Cristina, M. Paganuzzi, F. Boccardo

Research output: Contribution to journalArticle

Abstract

Testicular responsiveness to 5,000 IU of human chorionic gonadotropin was evaluated in 14 patients with prostate cancer who were being treated with a slow-releasing luteinizing hormone-releasing hormone agonist for a median of 21 months. Serum testosterone response to human chorionic gonadotropin was markedly reduced in most patients, with the median level increasing from 0.25 to 1.65 nmol per l. A second human chorionic gonadotropin test was repeated later in 5 patients who had been off treatment for a median of 6 months. Median serum testosterone levels increased to a maximum of 2.6 nmol per l compared to 28.2 nmol per l in an age-matched control group (p equals 0.008). Therefore, we conclude that long-term treatment with luteinizing hormone-releasing hormone agonists in elderly men leads to gonadal impairment that may not be as reversible as generally suggested.

Original languageEnglish
Pages (from-to)1235-2138
Number of pages904
JournalJournal of Urology
Volume142
Issue number5
Publication statusPublished - 1989

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Evidence for testicular impairment after long-term treatment with a luteinizing hormone-releasing hormone agonist in elderly men'. Together they form a unique fingerprint.

  • Cite this